Kinloch Capital LLC decreased its holdings in Kenvue Inc. (NYSE:KVUE – Free Report) by 21.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 121,888 shares of the company’s stock after selling 32,327 shares during the quarter. Kinloch Capital LLC’s holdings in Kenvue were worth $2,103,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of KVUE. Oak Thistle LLC acquired a new position in Kenvue in the fourth quarter valued at $1,563,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Kenvue by 25.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock worth $7,088,000 after acquiring an additional 84,219 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of Kenvue by 3,889.9% in the 4th quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock worth $53,056,000 after purchasing an additional 2,998,635 shares during the period. ICICI Prudential Asset Management Co Ltd raised its holdings in shares of Kenvue by 137.9% in the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 452,060 shares of the company’s stock worth $7,337,000 after purchasing an additional 262,000 shares during the period. Finally, Moors & Cabot Inc. lifted its stake in shares of Kenvue by 66.9% in the 3rd quarter. Moors & Cabot Inc. now owns 313,122 shares of the company’s stock valued at $5,082,000 after purchasing an additional 125,517 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.
Insider Activity
In other news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.59% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
View Our Latest Report on KVUE
Kenvue Price Performance
Shares of NYSE KVUE opened at $18.17 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The company has a market capitalization of $34.88 billion, a price-to-earnings ratio of 21.37, a PEG ratio of 1.37 and a beta of 0.54. The business has a 50-day moving average of $17.52 and a 200-day moving average of $17.57.
Kenvue (NYSE:KVUE – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The company’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the business posted $0.24 EPS. On average, equities analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.
Kenvue Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Featured Articles
- Five stocks we like better than Kenvue
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
